719 CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer
Main Authors: | Tyler Curiel, Yilun Deng, Ryan Reyes, Aravind Kancharla, Myrna Garcia, Harshita Gupta, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Anand Kornepati, Robert Svatek |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation
by: Yilun Deng, et al.
Published: (2021-04-01) -
Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy
by: Deyi Zhang, et al.
Published: (2021-03-01) -
Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial
by: Niannian Ji, et al.
Published: (2019-08-01) -
Stereo coding for the ITU-T G.719 codec
by: Jansson, Tomas
Published: (2011) -
Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
by: Bogang Wu, et al.
Published: (2018-11-01)